1921
Volume 83, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Since February 2002, the Drug Resources Enhancement against AIDS and Malnutrition Program has provided highly active antiretroviral therapy (HAART) and immunologic and virologic monitoring free of charge. We conducted a cohort study of persons infected with human immunodeficiency virus in Mozambique. Only persons treated with HAART with available CD4 cell counts at baseline and ≥ 1 CD4 cell count after HAART were included. Survival analysis was applied to evaluate the prognostic value of CD4 cell counts measured at three months. Possible confounders were considered. A total of 753 persons who started HAART included; 59% were females. Median age was 34 years (range = 16–67 years), and the median CD4 cell count at baseline was 172 cells/mm (interquartile range = 87–261 cells/mm , range = 0–1,322 cells/mm ). Overall, 105 persons (14%) died. Of these persons 54 (51%) developed AIDS before they died; 25 (3%) died during the first three months. After three months of therapy, the individual median CD4 cell count change from the baseline value was +101 cells/mm (interquartile range = +27 to +187 cells/mm , range = –723 to +310 cells/mm ). A median CD4 increment of 100 cells/mm in three months was associated with a mortality reduction of 50% compared with an increase of < 50 cells (relative hazard of death adjusted for baseline CD4 cell count = 0.54, 95% confidence interval = 0.30–0.95). A good initial response to HAART was associated with a significant reduction of mortality. This finding supports the effectiveness of HAART in resource-poor settings.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2010.09-0705
2010-11-05
2017-09-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/83/5/1128.html?itemId=/content/journals/10.4269/ajtmh.2010.09-0705&mimeType=html&fmt=ahah

References

  1. UNAIDS/WHO. AIDS Epidemic Update 2008. Available at: http://data.unaids.org/pub/GlobalReport/2008/jc1510_2008_global_report_pp29_62_en.pdf.
  2. World Health Organization, Towards Universal Access: Scaling Up Priority HIV/AIDS Intervention in the Health Sector: Progress Report; April 2007. Geneva: World Health Organization. Available at: http://www.who.int/hiv/mediacentre/univeral_access_progress_report_en.pdf.
  3. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R, , 2008. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22: 18971908.[Crossref]
  4. Bekker LG, Myer L, Orrel C, Lawn S, Wood R, , 2006. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J 96: 315320.
  5. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, Reuter H, Ntwana N, Goemaere E, , 2004. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18: 887895.[Crossref]
  6. Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, Peter PF, Gaolathe T, Mujugira A, Busang L, Vanderwarker C, Cardiello P, Johnson O, Thior I, Mazonde P, Moffat H, Essex M, Marlink R, , 2005. Initial response to highly active antiretroviral therapy in HIV-1 C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 40: 336342.[Crossref]
  7. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M, ; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) Groups, 2006. Mortality of HIV-1 infected patients in the first year of antiretroviral therapy; comparison between low-income and high-income countries. Lancet 367: 817824.[Crossref]
  8. Ivers LC, Kendrick D, Doucette K, , 2005. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 41: 217224.[Crossref]
  9. Lawn SD, Myer L, Harling G, Orrel C, Bekker LG, Wood R, , 2006. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South-Africa: implications for program evaluation. Clin Infect Dis 43: 770776.[Crossref]
  10. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, Abo Y, Salamon R, Bissagnene E, Seyler C, Eholié S, Anglaret X, , 2007. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in Wet Africa. AIDS 21: 24832491.[Crossref]
  11. Marazzi MC, Guidotti G, Liotta G, Palombi L, , 2005. DREAM: An Integrated Faith-Based Initiative to treat HIV/AIDS in Mozambique, Case Study. Perspectives and Practice in Antiretroviral Ttreatment. Sant' Egido Mozambique and Geneva: World Health Organization.
  12. Marazzi MC, Germano P, Liotta G, Guidotti G, Loureiro S, da Cruz Gomes A, Valls Blazques MC, Narciso P, Perno CF, Mancinelli S, Palombi L, , 2006. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med 7: 338344.[Crossref]
  13. Cleveland WS, , 1979. Robust locally-weighted regression and smoothing scatterplots. JASA 74: 829836.[Crossref]
  14. Rosen S, Fox MP, Gill CJ, , 2007. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4: e298.[Crossref]
  15. Etard JF, Ndiaye I, Thierry-Mieg M, Guèye NF, Guèye PM, Lanièce I, Dieng AB, Diouf A, Laurent C, Mboup S, Sow PS, Delaporte E, , 2006. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20: 11811189.[Crossref]
  16. De Cock KM, Gilks CF, Lo YR, Guerma T, , 2009. Can antiretroviral therapy eliminate HIV transmission? Lancet 373: 79.[Crossref]
  17. Chêne G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME, ; Antiretroviral Therapy Cohort Collaboration, 2003. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 362: 679686.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2010.09-0705
Loading
/content/journals/10.4269/ajtmh.2010.09-0705
Loading

Data & Media loading...

  • Received : 26 Nov 2009
  • Accepted : 16 Mar 2010

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error